OINDPnews


H&T Presspart banner

Business

Only one patent remains in contention in the United Therapeutics effort to delay final FDA approval of Liquidia’s Yutrepia treprostinil DPI

According to Liquidia Corporation, United Therapeutics has agreed to a court judgment finding that Liquidia did not infringe United Therapeutic's US Patent No. 9,604,901. In October 2021, an inter partes review by the US Patent Trial and Appeal Board (PTAB) determined that 7 of the 9 claims in that patent were invalid. United Therapeutics initially filed suit … [Read more...] about Only one patent remains in contention in the United Therapeutics effort to delay final FDA approval of Liquidia’s Yutrepia treprostinil DPI

EnBiotix raises $11 million in financing round led by Vectura for further development of ColiFin, murepavidin

EnBiotix, which is in the process of merging with inhaled murepavadin developer Polyphor, announced that it has raised $11 million in a financing round led by inhaled drug CDMO Vectura. Sanford Biosciences and the Cystic Fibrosis Foundation (CFF) also contributed to the financing, which will fund further development of ColiFin nebulized colistimethate sodium in … [Read more...] about EnBiotix raises $11 million in financing round led by Vectura for further development of ColiFin, murepavidin

Teva, Sandoz launch generics of Narcan naloxone nasal spray in US

Both Teva and Sandoz have announced launches of generic naloxone nasal spray for the reversal of opioid overdose in the US, with Teva claiming first-to-market status. The Sandoz version is an authorized generic of Emergent BioSolution's Narcan nasal spray. Teva's version of Narcan was approved by the FDA in April 2019. Opiant initially developed Narcan nasal … [Read more...] about Teva, Sandoz launch generics of Narcan naloxone nasal spray in US

ViraVac to develop intranasal COVID-19 vaccine based on Lancaster University technology

Lancaster University has announced that newly launched ViraCorp subsidiary ViraVac will develop a intranasal COVID-19 vaccine based on technology developed at Lancaster by Muhammad Munir, a lecturer in biomedicine. According to the announcement, "The company is set to announce a number of world-leading scientific partner organizations to take the vaccine through … [Read more...] about ViraVac to develop intranasal COVID-19 vaccine based on Lancaster University technology

Memo Therapeutics gets funding from Swiss government for development of inhaled mAb for COVID-19

Memo Therapeutics said that a Swiss funding program for COVID-19 medicines has granted the company CHF 10.5 million for clinical development of the company's COVAB 36 inhaled fully-human monoclonal antibody for the treatment of SARS-CoV-2 infection, and the Swiss government will have the option to purchase doses of the antibody following approval. Memo said that the … [Read more...] about Memo Therapeutics gets funding from Swiss government for development of inhaled mAb for COVID-19

Aerogen to supply nebulizers for delivery of CanSinoBio’s Convidecia inhaled COVID-19 vaccine

Nebulizer maker Aerogen and CanSino Biologics have signed a development and commercial supply deal for the use of Aerogen's vibrating mesh nebulizer technology for delivery of CanSinoBIO’s Convidecia inhaled vaccine against COVID-19. Terms of the deal were not disclosed. Earlier this year, CanSinoBio announced positive results from a Phase 1 trial of the Ad5-nCoV … [Read more...] about Aerogen to supply nebulizers for delivery of CanSinoBio’s Convidecia inhaled COVID-19 vaccine

Aerami Therapeutics to go public through SPAC merger

Inhaled drug developer Aerami Therapeutics has announced that it will go public through a merger with a special purpose acquisition company (SPAC) called FoxWayne Enterprises Acquisition Corp., and the resulting company’s common stock will be listed on the Nasdaq Capital Market. According to Aerami, the proceeds from the merger will be used for further development of … [Read more...] about Aerami Therapeutics to go public through SPAC merger

CF Foundation providing $3.5 million for development of Pulmocide’s inhaled opelconazole

The Cystic Fibrosis Foundation announced that it is providing $3.5 million for a Phase 2 study of Pulmocide Ltd's PC945 inhaled opelconazole for the prevention of pulmonary Aspergillus infections following lung transplantation. The CF Foundation noted that this is the organization's first investment in development of a drug specifically for treatment related to lung … [Read more...] about CF Foundation providing $3.5 million for development of Pulmocide’s inhaled opelconazole